fezolinetant (Veozah) Report issue

Small molecule Approved FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now
Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by for the treatment of sex hormone-related disorders. It is taken by mouth. It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017.   Wikipedia

Chemistry

  • SMILES: Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
  • InChIKey: PPSNFPASKFYPMN-SECBINFHSA-N
  • Mol. Mass: 358.4
  • ALogP: 2.46
  • ChEMBL Molecule:
    fezolinetant  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

fezolinetant

Organizations (3)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (2)


 

Hot Flashes

Menopause (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Healthy Volunteers (Phase 1)

Hot Flashes (Phase 3)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Menopause (Phase 2)

Vasomotor System (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue